Banta Andreea, Rosca Daniela, Rosca Ovidiu, Bogdan Iulia, Cerbulescu Teodor, Stana Loredana Gabriela, Hogea Elena, Nistor Daciana
Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Discipline of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Biomedicines. 2024 Nov 27;12(12):2707. doi: 10.3390/biomedicines12122707.
Patients with chronic kidney disease (CKD) are at increased risk of severe COVID-19 outcomes due to their compromised immune systems and chronic inflammatory state. This study aimed to evaluate and compare the inflammatory status of COVID-19 patients with CKD, stratified by creatinine clearance (CrCl) levels: CrCl < 30 mL/min, CrCl 30-60 mL/min, and CrCl > 60 mL/min. Multiple inflammatory scores combining laboratory parameters were assessed, including novel scores and established indices.
In this retrospective cohort study, 223 patients admitted with confirmed COVID-19 were included and divided into three groups based on CrCl levels: CrCl < 30 (n = 41), CrCl 30-60 (n = 78), and CrCl > 60 (n = 104). Laboratory parameters including C-reactive protein (CRP), interleukin-6 (IL-6), neutrophil-to-lymphocyte ratio (NLR), ferritin, platelet count, absolute neutrophil count (ANC), absolute lymphocyte count (ALC), and serum albumin were collected. Multiple inflammatory scores were calculated, including inflammation scores (IS1-IS4), the systemic inflammatory index (SII), the C-reactive protein-to-albumin ratio (CAR), the lymphocyte-to-C-reactive protein ratio (LCR), and the prognostic nutritional index (PNI). Statistical analyses were performed to compare inflammatory scores among groups and assess correlations with clinical outcomes.
The CrCl < 30 group exhibited significantly higher levels of inflammatory markers and inflammatory scores compared with the other groups ( < 0.001). Among the additional scores, CAR and SII were significantly elevated in patients with lower CrCl levels, while LCR and PNI were decreased. CAR showed a strong positive correlation with COVID-19 severity (r = 0.65, < 0.001), and PNI was inversely correlated with mortality (r = -0.58, < 0.001). Multivariate regression analysis indicated that lower CrCl levels, higher IS3 and CAR, and lower PNI were independent predictors of severe COVID-19 outcomes.
CKD patients with lower CrCl levels have an amplified inflammatory response during COVID-19 infection, as evidenced by elevated inflammatory scores. The additional inflammatory scores, particularly CAR and PNI, may serve as valuable tools for risk stratification and management of COVID-19 in CKD patients. Early identification of patients with high CAR and low PNI could improve clinical outcomes through timely therapeutic interventions.
慢性肾脏病(CKD)患者由于免疫系统受损和慢性炎症状态,发生严重新型冠状病毒肺炎(COVID-19)结局的风险增加。本研究旨在评估和比较根据肌酐清除率(CrCl)水平分层的COVID-19合并CKD患者的炎症状态:CrCl<30 mL/min、CrCl 30 - 60 mL/min和CrCl>60 mL/min。评估了多种结合实验室参数的炎症评分,包括新的评分和已确立的指标。
在这项回顾性队列研究中,纳入223例确诊为COVID-19的住院患者,并根据CrCl水平分为三组:CrCl<30(n = 41)、CrCl 30 - 60(n = 78)和CrCl>60(n = 104)。收集包括C反应蛋白(CRP)、白细胞介素-6(IL-6)、中性粒细胞与淋巴细胞比值(NLR)、铁蛋白、血小板计数、绝对中性粒细胞计数(ANC)、绝对淋巴细胞计数(ALC)和血清白蛋白在内的实验室参数。计算多种炎症评分,包括炎症评分(IS1 - IS4)、全身炎症指数(SII)、C反应蛋白与白蛋白比值(CAR)、淋巴细胞与C反应蛋白比值(LCR)和预后营养指数(PNI)。进行统计分析以比较各组间的炎症评分,并评估与临床结局的相关性。
与其他组相比,CrCl<30组的炎症标志物水平和炎症评分显著更高(<0.001)。在其他评分中,CAR和SII在CrCl水平较低的患者中显著升高,而LCR和PNI降低。CAR与COVID-19严重程度呈强正相关(r = 0.65,<0.001),PNI与死亡率呈负相关(r = -0.58,<0.001)。多因素回归分析表明,较低的CrCl水平、较高的IS3和CAR以及较低的PNI是严重COVID-19结局的独立预测因素。
CrCl水平较低的CKD患者在COVID-19感染期间炎症反应增强,炎症评分升高证明了这一点。额外的炎症评分,特别是CAR和PNI,可能是CKD患者COVID-19风险分层和管理的有价值工具。早期识别CAR高和PNI低的患者可通过及时的治疗干预改善临床结局。